Breaking News

Horizon Adds Sanofi Compiegne Site for DUEXIS

Gains FDA approval as an additional manufacturing facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Horizon Pharma, Inc. has received approval from the FDA to use Sanofi’s manufacturing site in Compiegne, France to manufacture DUEXIS (ibuprofen/famotidine), a single-tablet combination of ibuprofen (800 mg) and famotidine (26.6 mg). Valeant’s manufacturing site in Laval, Quebec, previously owned and operated by Sanofi, serves as the primary commercial manufacturing site for DUEXIS.    “We have had a successful long-term partnership with Sanofi and are pleased with the FDA&#821...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters